High-dose 17β–estradiol treatment prevents development of heart failure post–myocardial infarction in the rat
- 103 Downloads
Prognosis of heart failure remains poor despite therapeutic advances, such as angiotensin converting enzyme inhibition or β-receptor blockade. Thus, more effective forms of treatment are urgently needed. Since estrogens have been shown to modulate migration and proliferation of cardiac fibroblasts and to modulate the expression of estrogen receptors of cardiomyocytes we examined whether high-dose estrogen treatment can affect post-myocardial infarction left ventricular remodeling.
Female rats were treated with 17β-estradiol (7.5 mg/90 d) or placebo for ten weeks, starting two weeks prior to experimental myocardial infarction. Eight weeks after infarction, in vivo echocardiographic and hemodynamic measurements as well as isolated heart perfusion were performed.
In vivo, chronic estrogen treatment almost completely prevented the development of all signs of heart failure that occur in untreated infarcted hearts, such as increased left ventricular diameters (dilatation), reduced fractional shortening (systolic dysfunction) or increased left ventricular end–diastolic pressure (diastolic dysfunction). In vitro, the right- (indicating structural dilatation) and downward (indicating left ventricular dysfunction) shift of left ventricular pressure-volume curves occurring in untreated infarcted hearts was completely prevented by estrogen.
High dose estradiol treatment prevented development of post-MI remodeling, as assessed by in vivo and in vitro parameters of LV dysfunction. Estrogen may hold the potential of becoming a new form of heart failure treatment.However, the mechanisms responsible for this striking and unexpected beneficial action of estrogen in heart failure remain to be elucidated.
Key wordsestrogen remodeling myocardial infarction heart failure
Unable to display preview. Download preview PDF.
- 3.Brutsaert DL (1993) Endocardial and coronary endothelial control of cardiac performance. News Physiol Sci 8:82–86Google Scholar
- 4.CIBIS, Investigators and Committees (1994) A randomized trial of b–blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765–1773Google Scholar
- 17.Horn M, Neubauer S, Frantz S, Hügel S, Hu K, Gaudron P, Schnackerz K, Ertl G (1996) Preservation of left ventricular mechanical function and energy metabolism in rats after myocardial infarction by the angiotensin–converting enzyme inhibitor quinapril. J Cardiovasc Pharmacol 27:201–210PubMedCrossRefGoogle Scholar
- 18.Hu K, Gaudron P, Ertl G (1998) Longterm effects of beta–adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction. Importance of timing of treatment and infarct size. J Am Coll Cardiol 31:692–700PubMedCrossRefGoogle Scholar
- 22.Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, and for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613PubMedCrossRefGoogle Scholar
- 29.Leitzbach D, Weckler N, Madajka M, Malinski T, Wiemer G, Linz W (2005) Restoration of endothelial function via enhanced nitric oxide synthesis after long–term treatment of raloxifene in adult hypertensive rats. Arzneimittelforschung 2005:86–92Google Scholar
- 42.Sahn DJ, DeMaria A, Kisslo J, Weyman A, and The Committee on M–mode standardization of the American Society of Echocardiography (1978) Recommendations regarding quantitation in M–mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMedGoogle Scholar